CSI Market
Sign In | Register

Voyager Therapeutics Inc (VYGR) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access VYGR quarterly Cash Flow →
A period-by-period view of cash flow from Voyager Therapeutics Inc to Dec 31 2021 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-119.72
Depreciation & amortization4.06
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.14
Share-based Compensation14.79
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
In Kind Research And Development Expenses-
Increase Decrease In Right Of Use Assets-
Increase Decrease In Lease Liabilities-
Increase Decrease In Operating Lease Liability-7.23
Increase Decrease In Deferred Lease Incentive Credit From Lessor-
Gain Loss On Termination Of Lease-
Operating Lease Impairment Loss-
Increase Decrease In Collaboration Receivables4.87
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.26
Increase (Decrease) in Accounts Payable1.02
Increase (Decrease) in Accrued Liabilities-2.50
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.62
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-31.26
Discontinued operations0.00
Net Cash flow from Operating Activities-132.47
Investing Activities
Capital Expenditures-2.60
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities261.97
Payments to Acquire Marketable Securities-133.93
Real Estate Investments0.00
Proceeds From Maturity Of Marketable Securities-
Proceeds From Sales Of Marketable Investments-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities125.45
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.82
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Tranche Rights-
Proceeds From Issuance Of Redeemable Convertible Preferred Stock Net Of Discount And Issuance Costs-
Deferred Initial Public Offering Costs-
Proceeds From Issuance Of Common Stock And Restricted Stck-
Proceeds From Issuance Of Common Stock And Restricted Stock-
Proceeds From Issuance Of Stock Net Of Discount And Issuance Costs-
Proceeds From Issuance Of Stock In Connection With Neurocrine Collaboration Agreement-
Proceeds From Issuance Of Common Stock In Connection With2023 Novartis Collaboration Agreement-
Proceeds From Issuance Of Common Stock In Connection With2023 Neurocrine Collaboration Agreement-
Proceeds From Issuance Of Common Stock and Pre Funded Warrants In Connection With2023 Novartis Stock Purchase Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.82
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-135.06
Total Cash Flow-6.21
4 historic quarters locked

Sign in to unlock the full Voyager Therapeutics Inc cash flow history.

Sign In Create Free Account

About Voyager Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-025197

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License